High levels of low-density lipoprotein cholesterol (LDL-C) are directly associated with an increased risk of cardiovascular disease. Reducing LDL-C levels reduces the incidence of cardiovascular events. Several lipid-lowering approaches are available to achieve the LDL-C levels recommended by current guidelines, statins being the first-line therapy. However, many patients cannot achieve the recommended LDL-C levels with current therapies. The discovery of the role of proprotein convertase subtilisin kexin 9 (PCSK9) in the regulation of plasma LDL-C levels suggested it as a potential pharmacologic target and led to the development of PCSK9 inhibitors for the management of LDL-C levels.
|Titolo:||Proprotein Convertase Subtilisin Kexin 9 Inhibitors|
CATAPANO, ALBERICO LUIGI (Corresponding)
|Parole Chiave:||Alirocumab; Cardiovascular disease; Evolocumab; Hypercholesterolemia; LDL-C; Monoclonal antibodies; PCSK9; Proprotein convertase subtilisin kexin 9; Cardiology and Cardiovascular Medicine|
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||mag-2018|
|Digital Object Identifier (DOI):||10.1016/j.ccl.2017.12.006|
|Appare nelle tipologie:||01 - Articolo su periodico|